SCHEMBL2029048

SCHEMBL2029048

CCCCCCC(=O)OCl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.61
LMNA P02545 2/20 0.57
TSHR P16473 6/20 0.57
ALDH1A1 P00352 3/20 0.56
PAM P19021 2/20 0.55
CES2 O00748 3/20 0.54
CES1 P23141 3/20 0.54
MAPT P10636 1/20 0.53
MAPK1 P28482 1/20 0.53
PPARG P37231 6/20 0.52
PPARD Q03181 6/20 0.52
PPARA Q07869 6/20 0.52
HDAC11 Q96DB2 5/20 0.52
GPR84 Q9NQS5 4/20 0.52
TLR2 O60603 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
FABP4 P15090 2/20 0.52
PTPN1 P18031 2/20 0.52
SLC22A6 Q4U2R8 1/20 0.52
SLC22A8 Q8TCC7 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9844549 1.00 DGKA (0.61) DGKALMNATSHRALDH1A1PAM
SCHEMBL177409 1.00 DGKA (0.61) DGKALMNATSHRALDH1A1PAM
SCHEMBL7647987 1.00 DGKA (0.61) DGKALMNATSHRALDH1A1PAM
SCHEMBL10642835 1.00 DGKA (0.61) DGKALMNATSHRALDH1A1PAM
SCHEMBL539005 1.00 DGKA (0.61) DGKALMNATSHRALDH1A1PAM
SCHEMBL926254 1.00 DGKA (0.61) DGKALMNATSHRALDH1A1PAM
SCHEMBL4152672 1.00 DGKA (0.61) DGKALMNATSHRALDH1A1PAM
SCHEMBL2189614 1.00 DGKA (0.61) DGKALMNATSHRALDH1A1PAM
SCHEMBL7260301 1.00 DGKA (0.61) DGKALMNATSHRALDH1A1PAM
SCHEMBL2222481 1.00 DGKA (0.61) DGKALMNATSHRALDH1A1PAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2707364-B1 PROCESS FOR THE MANUFACTURE OF DABIGATRAN ETEXILATE AND INTERMEDIATES THEREOF EGIS GYÓGYSZERGYÁR ZRT (HU) 2016-08-24 EP claimed
US-9260421-B2 Pharmaceutical intermediates and process for the preparation thereof EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2016-02-16 US claimed
US-20140155614-A1 PHARMACEUTICAL INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2014-06-05 US claimed
EP-2707364-A1 PROCESS FOR THE MANUFACTURE OF DABIGATRAN ETEXILATE AND INTERMEDIATES THEREOF EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság (HU) 2014-03-19 EP claimed
WO-2013024384-A1 IMPROVED PROCESS FOR PREPARATION OF DABIGATRAN ETEXILATE AND ITS NOVEL INTERMEDIATE ALEMBIC PHARMACEUTICALS LIMITED (IN) 2013-02-21 WO claimed
WO-2012153158-A1 PROCESS FOR THE MANUFACTURE OF DABIGATRAN ETEXILATE AND INTERMEDIATES THEREOF EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság (HU) 2012-11-15 WO claimed
EP-2262771-A1 A METHOD FOR THE PREPARATION OF DABIGATRAN Zentiva, K.S. (CZ) 2010-12-22 EP claimed
WO-2009111997-A1 A METHOD FOR THE PREPARATION OF DABIGATRAN ZENTIVA, K.S. (CZ) 2009-09-17 WO claimed
CN-112144141-B Copolymerized flame-retardant polyamide fiber and preparation method thereof 东华大学 2021-10-26 CN disclosed
CN-112225892-B Copolymerization flame-retardant polyamide and preparation method thereof 东华大学 2021-10-08 CN disclosed
CN-109432508-B Decalcified bone matrix material with bone growth promoting and antibacterial functions as well as preparation method and application thereof 中国人民解放军总医院第一附属医院 2021-05-28 CN disclosed
WO-2021037362-A1 OPTIMIZED ANALYTE DERIVATIZATION FOR SYNERGISTIC APPLICATION WITH CRYSTAL SPONGE METHOD MERCK PATENT GMBH (DE) 2021-03-04 WO disclosed
CN-112225892-A Copolymerization flame-retardant polyamide and preparation method thereof 东华大学 2021-01-15 CN disclosed
CN-112144141-A Copolymerized flame-retardant polyamide fiber and preparation method thereof 东华大学 2020-12-29 CN disclosed
WO-2011075684-A1 PRODRUGS OF INHIBITORS OF PLASMA KALLIKREIN ACTIVESITE PHARMACEUTICALS, INC. (US) 2011-06-23 WO disclosed
EP-2262771-A1 A METHOD FOR THE PREPARATION OF DABIGATRAN Zentiva, K.S. (CZ) 2010-12-22 EP disclosed
WO-2010045900-A1 A METHOD FOR THE PREPARATION OF DABIGATRAN AND ITS INTERMEDIATES ZENTIVA, K.S. (CZ) 2010-04-29 WO disclosed
WO-2009111997-A1 A METHOD FOR THE PREPARATION OF DABIGATRAN ZENTIVA, K.S. (CZ) 2009-09-17 WO disclosed
EP-1968949-A1 IMPROVED PROCESS FOR THE PREPARATION OF THE SALTS OF 4-(BENZIMIDAZOLYLMETHYLAMINO)-BENZAMIDES Boehringer Ingelheim International GmbH (DE) 2008-09-17 EP disclosed
WO-2007071743-A1 IMPROVED PROCESS FOR THE PREPARATION OF THE SALTS OF 4-(BENZIMIDAZOLYLMETHYLAMINO)-BENZAMIDES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155614-A1 PHARMACEUTICAL INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF TFPI, VKORC1, VKORC1L1 DGKA 1828/4885LMNA 2007/4885TSHR 1936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.